Get the Stockscreener App
736.53
0.50%
3.66
Regeneron Pharmaceuticals Inc stock is traded at $736.53, with a volume of 535.84K.
It is up +0.50% in the last 24 hours and down -6.42% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$732.87
Open:
$744.995
24h Volume:
535.84K
Relative Volume:
0.70
Market Cap:
$77.87B
Revenue:
$14.34B
Net Income/Loss:
$4.50B
P/E Ratio:
17.72
EPS:
41.5626
Net Cash Flow:
$3.77B
1W Performance:
-2.69%
1M Performance:
-6.42%
6M Performance:
+29.70%
1Y Performance:
+11.85%
1-Day Range:
$735.00
$750.00
1-Week Range:
$727.88
$771.23
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
681.85 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
143.98 | 29.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment | Business Information & News | FE - Westlaw Today
Small Biotech Zips Higher On Its Regeneron-Rivaling Test Results - Investor's Business Daily
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment - Reuters
Nordea Investment Management AB Acquires 74,350 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Tokenized Stock (Ondo) price today, REGNon to USD live price, marketcap and chart - CoinMarketCap
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality - BioSpace
How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset - Yahoo Finance
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Weak Share Momentum And Franchise Outlook - simplywall.st
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Why Regeneron Pharmaceuticals (REGN) is one of the top gene therapy stocks to buy according to hedge funds - MSN
Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN) - The Globe and Mail
Union Bancaire Privee UBP SA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is It Time To Revisit Regeneron (REGN) After Recent Share Price Pullback? - simplywall.st
Swiss Life Asset Management Ltd Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $860 - Moomoo
PCSK9 Inhibitor Market to Reach US$7.67 Billion by 2033 at 16.5% - openPR.com
Atopic Dermatitis Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie - Barchart
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead? - The Globe and Mail
Formycon secures license date for aflibercept biosimilar FYB203 in Europe - The Pharma Letter
Hudson Bay Capital Management LP Sells 31,367 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Groupama Asset Managment Sells 5,169 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Lower LDL Is Better In New ACC/AHA Guidelines, Making The Case For Add-Ons To Statins - Citeline News & Insights
Trading Action: What are the future prospects of Regeneron Pharmaceuticals Inc2026 Volume Leaders & AI Driven Stock Reports - baoquankhu1.vn
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed On Friday - MSN
Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds? - MSN
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
Caerus Investment Advisors LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD - The Globe and Mail
Regeneron: EPS Set to Jump 18% in 2027 as Obesity Bet Reframes the Investment Case - TIKR.com
Holocene Advisors LP Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Brevan Howard Capital Management LP Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
California Public Employees Retirement System Sells 111,602 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Boothbay Fund Management LLC Buys 1,541 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Behavioral Patterns of REGN and Institutional Flows - Stock Traders Daily
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease - TipRanks
Hamilton Wealth LLC Acquires New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Gotham Asset Management LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Distillate Capital Partners LLC - MarketBeat
Aquatic Capital Management LLC Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Alliancebernstein L.P. Sells 63,344 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy? - Insider Monkey
Bank of Nova Scotia Boosts Regeneron Pharmaceuticals Holdings - National Today
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Cannell & Spears LLC - MarketBeat
Chevy Chase Trust Holdings LLC Lowers Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bank of Nova Scotia Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN) Valuation Check After Recent Share Price Cooling - simplywall.st
Suvretta Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Dodge & Cox - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.70%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):